Institutional and Insider Ownership
1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Quantum Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum Biopharma | N/A | -84.21% | -62.63% |
| Quantum Biopharma Competitors | -3,418.95% | -220.73% | -32.92% |
Risk and Volatility
Quantum Biopharma has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Quantum Biopharma’s peers have a beta of 3.88, indicating that their average share price is 288% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Quantum Biopharma | N/A | -$17.90 million | -0.22 |
| Quantum Biopharma Competitors | $1.74 billion | $160.22 million | -5.66 |
Quantum Biopharma’s peers have higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Quantum Biopharma peers beat Quantum Biopharma on 6 of the 9 factors compared.
About Quantum Biopharma
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
